Menin Links Estrogen Receptor Activation to Histone H3K4 Trimethylation

Koen M.A. Dreijerink,1,2 Klaas W. Mulder,1 G. Sebastiaan Winkler,1 Jo W.M. Höppner,3 Cornelis J.M. Lips,2 and H.Th. Marc Timmers1

Departments of 1Physiological Chemistry, 2Internal Medicine and Endocrinology, and 3Metabolic and Endocrine Diseases, University Medical Center Utrecht, Utrecht, the Netherlands

Abstract
The product of the multiple endocrine neoplasia type 1 (MEN1) tumor suppressor gene, menin, is an integral component of MLL1/MLL2 histone methyltransferase complexes specific for Lys4 of histone H3 (H3K4). We show that menin is a transcriptional coactivator of the nuclear receptors for estrogen and vitamin D. Activation of the endogenous estrogen-responsive TFF1 (pS2) gene results in promoter recruitment of menin and in elevated trimethylation of H3K4. Knockdown of menin reduces both activated TFF1 (pS2) transcription and H3K4 trimethylation. In addition, menin can directly interact with the estrogen receptor-α (ERα) in a hormone-dependent manner. The majority of disease-related MEN1 mutations prevent menin-ERα interaction. Importantly, ERα-interacting mutants are also defective in coactivator function. Our results indicate that menin is a critical link between recruitment of histone methyltransferase complexes and nuclear receptor-mediated transcription. (Cancer Res 2006; 66(9): 4929-35)

Introduction
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominantly inherited cancer syndrome with high penetrance and variable expression. MEN1 is characterized by the combined occurrence of tumors in the parathyroids, the endocrine pancreas/duodenum, and the anterior pituitary gland. Less frequently, adrenal tumors and carcinoid tumors of the thymus, bronchus, or stomach occur (1). The clinical manifestations can result from hormone hypersecretion, mass effect of tumor growth, malignancy, or any combination thereof. The MEN1 syndrome affects about 2 to 3 per 100,000 individuals and is caused by germ line mutations of the MEN1 tumor suppressor gene (2). Although the majority of these mutations result in truncated MEN1 products, a significant proportion (≥20%) are missense mutations, presumably yielding nonfunctional proteins. In MEN1-associated tumors, loss of heterozygosity of the wild-type MEN1 allele is observed (3), fulfilling the "two-hit" hypothesis of Knudson for a tumor suppressor gene (4).

MEN1 orthologues are found in the genomes of higher eukaryotes, and the gene displays a ubiquitous expression pattern in human tissues (2). The product of the MEN1 gene, menin, is a nuclear protein (2). Menin interacts with several nuclear proteins [including JunD, nuclear factor-κB (NF-κB), HDAC1/2, and Sin3A], and it can attenuate JunD- and NF-κB-mediated transcription (5–7). Menin was also isolated as a negative regulator of the hTERT gene (8). Recently, menin was found to be associated in MLL1/MLL2 histone methyltransferase (HMT) complexes, which can direct modification of histone H3 Lys4 (H3K4; refs. 9, 10). Trimethylation of H3K4 (H3K4me3) is linked to gene activity in yeast (11). Consistent with this, H3K4me3 and MLL1 localize at the 5′ ends of actively transcribed genes in human cells (12). Several Hox genes and the genes for the p18 and p27 cyclin-dependent kinase inhibitors are targets for menin-HMT complexes (9, 10, 13), but how these complexes are recruited remains unknown. The activity of the MEN1 gene is clearly associated with endocrine function. Nuclear receptors play an important role in endocrine processes and in human cancers. The nuclear receptor family represents a class of transcription factors and includes the receptors for steroid and thyroid hormones but also receptors for derivatives of vitamins A and D. Multiple coactivator and corepressor complexes are responsible for regulation of nuclear receptor-mediated transcription (14). In this study, we report that menin can act as a direct coactivator for estrogen receptor α (ERα)-mediated transcription. We provide data indicating that menin serves as a critical link between activated ERα and H3K4 trimethylation and is involved in activation of transcription of the estrogen-regulated TFF1 gene. These results provide a molecular mechanism for recruitment of H3K4 HMT complexes and could provide an explanation for the clinical manifestations of the MEN1 syndrome.

Materials and Methods

Plasmids and mutagenesis. The baculovirus transfer vector, pHBlMENhis, was constructed by insertion of a BamHI-HindIII fragment from pBacM1-H (gift from G. Weber), which carries the human MEN1 cDNA, into pFastBac (Invitrogen, Breda, the Netherlands). pEG202NLS-menin for expression of the LexA-menin fusion protein was constructed by PCR amplification of the MEN1 cDNA from pCDNA3.1+ (gift of G. Weber) using oligos M2-BamHI-F1, 5′-GATCATCGGATCCGGTAAAGCGCG-CAAGA-3′ and M610-B-N-R, 5′-GATCATCGGATCCGGCGCTCAGGCCTTGCCGCTGCC-3′ and insertion using BamHI and NotI of pEG202NLS. pEG202NLS is similar to pEG202 (15) but includes a SV-LT nuclear localization signal introduced in the multiple cloning site. MEN1 missense mutations were introduced by site-directed mutagenesis in the menin expression vector pCDNA3.1+ and pEG202NLS-menin as described in the QuickChange protocol from Stratagene (La Jolla, CA). Construction of pSG424mERo(A2) and GST-mERo(A2) was performed by S. Agarwal, and pGEX-SxGST-65 (gift from L. Burns) have been described (5, 6, 16). pXj440hVDR(De) for expression of the Gal4-fusion with the AF2 domain of human vitamin D receptor (VDR) was provided by G. Weber. pXJ440hVDR(A2) has been described (5, 17). B42-mERo(A2), B42-hERo(A2), and B42-m Erα (M547A/L548A) (18) were constructed in the pGF4-5 vector.

Requests for reprints: H.Th. Marc Timmers, Department of Physiological Chemistry, University Medical Center Utrecht, Utrecht, the Netherlands. Phone: 31-30-253-8961; Fax: 31-30-253-9035; E-mail: h.t.m. timmers@med.uu.nl.

©2006 American Association for Cancer Research. doi:10.1158/0008-5472.CAN-05-4461

www.aacrjournals.org 4929 Cancer Res 2006; 66: (9). May 1, 2006
Antibodies and immunoblotting. Polyclonal menin antibodies (20.145-436 for chromatin immunoprecipitation experiments) were generated by immunization of a rabbit with purified recombinant menin. After three immunizations, plasma was obtained by plasmapheresis. Antibodies were purified by binding to an affinity-matrix consisting of recombinant menin (4 mg/ml) attached to Affi-Gel 10 beads (Bio-Rad, Veenendaal, the Netherlands) and eluted with 100 mM/L glycine (pH 2.5).

Antibodies against menin were purchased from Bethyl Laboratories (Montgomery, TX, A300-105A), against Ebox from Santa Cruz Biotechnology (Santa Cruz, CA), and against the histone H3 COOH terminus, H3Kme2, and H3Kme3 from Abcam (Cambridge, United Kingdom). For TATA-binding protein (TBP) detection, 1F8 monoclonal antibodies were used, and for the chromatin immunoprecipitation of RNA polymerase II, SWG16 antibodies were used. Control rabbit immunoglobulins were purchased from Sigma-Aldrich Chemie (Zwijndrecht, the Netherlands).

For immunoblotting, proteins were separated by SDS-PAGE and blotted to nitrocellulose membrane (Protran BA83, Schleicher and Schuell, Dassel, Germany). Blots were blocked for >1 hour in TBST containing 5% dried milk (ELK, Campina, Woerden, the Netherlands) and subsequently incubated with appropriate primary and secondary antibodies. Bands were visualized by enhanced chemiluminescence (Western lightning, Perkin-Elmer, Wellesley, MA).

Cell lines and transient transfections. Cos7 (African green monkey kidney), 293T (human embryonic kidney), and MCF-7 (human breast cancer, provided by R. Bernards, NKI) cells were routinely cultured in DMEM (Cambrex, Rockville, NJ) supplemented with 10% fetal bovine serum, 2 mM/L L-glutamine, 100 units/ml penicillin, and 100 mg/ml streptomycin. For reporter experiments, Cos7 cells were seeded at 8 to 10 x 10^4 cells per well in DMEM and 293T cells at 1.5 x 10^5 cells per well in DMEM without phenol red (Life Technologies, Breda, the Netherlands) containing 5% dextran-coated, coal-treatment serum, 1-glutamine, penicillin, and streptomycin, in 12-well plates. All manipulations were done at 24-hour intervals. In Ga4ERx reporter experiments, Cos7 cells were washed with PBS, and medium was changed to DMEM without phenol red on day 2. DNA (750 ng per well) was transfected using FuGene 6 reagent (Promega Diagnostics, Almere, the Netherlands). Transfection mixtures consisted of 200 ng luciferase reporter, 25 ng pCMV-Renilla and 5 ng pSG424-mER, pX4H40hVDR(ΔE), or pH4-VP16 expression vector and supplemented with 520 ng pC DNA3.1+ and/or empty pcDNA3 plasmid. Twenty-four hours after transfection, the medium was changed to medium containing both ligand [10 mM/L 17β-estradiol (E2, Sigma), 100 mM/L 1,25-dihydroxyvitamin D3 (Sigma, or ethanol vehicle). Luciferase and Renilla activities were measured on a Lumat LB9507 luminometer (EG&G Berthold, Bad Wildbad, Germany) using the Dual Luciferase kit (Promega, Leiden, the Netherlands). Luciferase activities were corrected for CMV-Renilla values and are expressed as relative to transfections without menin. Each transfection was done at least thrice to ensure reproducibility of the observations.

Protein expression and purification. Recombinant baculoviroses expressing eIF3is-tagged menin protein were obtained using pFBmMEMnis in the Bac-to-Bac baculovirus system (Invitrogen). Sf9 cells were grown in a 5-liter bioreactor (Applikon, Schiedam, the Netherlands). At a density of 5 x 10^5 cells/ml, recombinant virus was added. Cells were harvested 5 days after infection and resuspended in lysis buffer [50 mM/L Tris-HCl (pH 8), 300 mM/L KCl, 5 mM/L β-mercaptoethanol, 1 mM/L phenylmethylsulfonyl fluoride (PMSF), 0.1% NP40, 1 µg/ml aprotinin, 1 µg/ml leupeptin, and 1 µg/ml pepstatin A].

The lysate was loaded onto a 40-ml Ni-NTA agarose (Qiagen, Venlo, the Netherlands) column, which was washed with lysis buffer containing 1 mM/L imidazole and subsequently with wash buffer [20 mM/L Tris-HCl (pH 8), 20% glycerol, 100 mM/L KCl, 2 mM/L β-mercaptoethanol, and 16 mM/L imidazole]. Bound proteins were eluted with three column volumes of wash buffer containing 300 mM/L imidazole. Menin-containing fractions were pooled and dialyzed against buffer T50 [20 mM/L Tris-HCl (pH 8), 50 mM/L KCl, 20% glycerol, 0.5 mM/L EDTA, 0.5 mM/L PMSF, and 1 mM/L DTT]. The protein was subsequently applied to a MonoQ HR10/10 anion exchange column (Amersham Biosciences, Roosendaal, the Netherlands), which was developed by a 50 to 1,000 mM/L KCl linear gradient in buffer T over 15 column volumes. The menin protein elutes at a conductivity of 100 to 200 mM/L KCl.

Yeast two-hybrid experiments. EGY48 cells were transformed with the B42-Ebox(AF2) constructs and the indicated LexA-menin constructs. Cells were grown overnight at 30°C in 2% galactose/1% sucrose containing 5C medium lacking the appropriate amino acids and in the presence of vehicle, 1 mM/L E2, or 1 mM/L 4OH-tamoxifen. Lysates were prepared, and the LacZ activity was determined by a liquid β-galactosidase assay, as described previously (19). Values were corrected for the total amount of protein present in the extract.

Protein-binding experiments. GST-NF-κB (p65-RelA) and GST-JunD proteins were expressed in Escherichia coli strain BL21(DE3); glutathione S-transferase (GST) and GST-mE ro(ΔF) were expressed in strain DH5α. Expression and lysis procedures have been described previously (19). Purified GST-mEro(AF2) or GST and soluble lysates containing equivalent amounts of GST-p65 or GST-JunD were bound to glutathione agarose beads (Sigma) for 4 hours at 4°C in binding buffer [50 mM/L Tris-HCl (pH 8), 10% glycerol, 100 mM/L NaCl, 10 mM/L MgCl2, 0.5 mM/L PMSF, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin A, 1 mM/L NaF, 1 mM/L Na3VO4, and 0.5 mM/L DTT]. After washing with binding buffer, purified menin protein (8 µg/ml) was added. Binding experiments with GST and GST-mE ro(AF2) were carried out in the presence of 1 mM/L E2 or ethanol for 4 hours at 4°C. Glutathione beads were washed thrice with excess binding buffer, and eluted proteins were analyzed by immunoblotting.

Small interfering RNA knockdown and analysis of TFF1/pS2 gene expression. MCF-7 cells were trypsinized and resuspended in electroploration buffer [2 mM/L HEPES (pH 7.2), 15 mM/L phosphate buffer (pH 7.2), 250 mM/L mannitol, and 1 mM/L MgCl2]. Resuspended cells (~10^6) were mixed with 2 µg of duplex small interfering RNAs (siRNA: Dharmacon, Chicago, IL) against lamin (Lamin-SiGLO), or menin (Menin#1 (10) and Menin#2, which has been published as MEN1-10 (20)) and electroporated in 1-mm cuvettes at 140 V, 16 pulses of 1.5 milliseconds (Gene Pulser X-cell, Bio-Rad). Cells were grown in DMEM without phenol red. After 72 hours, medium containing 10 mM/L E2 or ethanol vehicle was added for 3 hours before cell harvesting. Total RNA was extracted using the RNeasy kit (Qiagen) and subsequently treated with DNase (DNA-free, Ambion, Huntington, United Kingdom); 120 ng of total RNA was used for cDNA synthesis (Superscript II, Invitrogen). Expression of TFF1/pS2 and β-actin mRNA expression were analyzed by quantitative PCR on a Chromo-4-equipped PCR cycler (MJ Research, Bio-Rad) using primers RT-PSS-OF, 5'-ATACATCGAGCTCCCTCCA-3'; RT-PSS-REV, 5'-AAGGCTGTTCTGGAGGTCCG-3'; RT-B-ACT-NF, 5'-AGAAATCTGGCACCACCCACC-3'; and RT-B-ACT-REV, 5'-AGAGGGTGACAGGGAATGAC-3' and normalized against a standard reference cDNA from untreated MCF-7 cells. The experiment shown is a representative experiment done in duplicate and analyzed by reverse transcription-PCR in duplicate.

Chromatin immunoprecipitation experiments. Subconfluent cultures of MCF-7 cells (~5 x 10^6 cells) were cross-linked by addition of 1% formaldehyde in PBS for 10 minutes at 37°C. Cells were lysed in buffer [50 mM/L Tris-HCl (pH 7.9), 1% SDS, 10 mM/L EDTA, 1 mM/L DTT, and protease inhibitors]. The lysate was sonicated thrice for 15 seconds in a Bioreruptor (Diagenode, Liege, Belgium). These mild sonication conditions result in DNA fragments of 2 to 10 kb. Soluble material was diluted 10 times in dilution buffer [20 mM/L Tris-HCl (pH 7.9), 2 mM/L EDTA, 150 mM/L NaCl, 1 mM/L DTT, 0.5% Triton X-100, and protease inhibitors] and incubated with appropriate antibody or control rabbit IgG overnight at 4°C. Protein A and protein G beads (1:1) were blocked in buffer TE [10 mM/L Tris-HCl (pH 8.1), 1 mM/L EDTA] containing 1 mg/ml/herring sperm and 1 mg/ml bovine serum albumin overnight at 4°C. Beads were washed four times in buffer TE and incubated with the chromatin for 3 hours at 4°C. Subsequently, the beads were washed four times with wash buffer [20 mM/L Tris-HCl (pH 8), 250 mM/L NaCl 2 mM/L EDTA, 0.05% SDS, 0.25% NP40, and protease inhibitors] and once in buffer TE. The beads were resuspended in elution buffer (100 mM/L NaHCO3, 1% SDS) and placed at 65°C overnight to reverse DNA/protein cross-links.
Proteinase K was added for 30 minutes at 37°C. Eluted DNA was purified by Qiaquick PCR purification columns (Qiagen). Binding of TFF1/pS2 promoter DNA was assessed by quantitative PCR using primers PS2-FOR, 5'-CCTGGTAATAGTGGTTGGA-3' and PS2-REV, 5'-TCTTGGCTAGGGGATCTGGAGA-3' and normalized against input samples from the same experiment. Analysis of exon 2 DNA of myoglobin, a non–E2-responsive gene, was used as an internal control. Primers used were MYO EX2_FW, 5'-AGTTTCAGAACCTCAAGACCTG-3' and MYO_EX2_RV, 5'-TGCGCACCATGCTCTTTAAGTC-3' (sequences from S. Denissov).

Results

Menin is a coactivator of nuclear receptor mediated transcription. Association of menin activity with endocrine functions and the presence of sequence motifs involved in recruitment of cofactors (see below) suggested that menin can act as a cofactor for nuclear receptors. We tested this hypothesis in a luciferase reporter assay measuring activation by the ERα. A reporter construct bearing multiple binding sites for the yeast Gal4 activator and an expression vector for a Gal4 DNA-binding domain fusion with the ligand binding (AF2) domain of ERα was used. We found that menin overexpression in Cos7 cells augmented ERα-mediated transcription in an E2-dependent manner (Fig. 1A). Menin also increased VDR-activated transcription to about 2-fold (Fig. 1B). Transient transfection assays using 293T human embryonic kidney cells showed a similar stimulation of ERα-activated transcription (Fig. 1C). Whereas coactivation of ERα by menin in Cos7 cells showed a clear optimum, 293T cells displayed a linear dose-response curve. Possibly, the optimum observed in Cos7 cells resulted from titration of limiting factors by excessive overexpression of menin. The nonrelated activator Gal4VP16 was included in these assays as a negative control for coactivation by menin. As reported previously (6), menin did not affect activation by VP16 (Fig. 1D), indicating that in our transfections, menin displayed transcription activator specificity. Thus, the transient reporter assays indicate that menin can act as a coactivator for the nuclear receptors for estrogen and vitamin D.

Menin is an activator of ligand-induced TFF1 gene expression. To investigate whether menin is involved in regulation of endogenous nuclear receptor–responsive genes, we analyzed transcriptional activation of the TFF1/pS2 gene after siRNA-mediated knockdown of menin. The TFF1 gene (pS2) has served as a model to study effects of coactivators of ERα (21, 22). Two different effective siRNAs against menin or nuclear lamin (as a control) were transfected into breast carcinoma–derived MCF-7 cells. Quantitative mRNA analysis of the transfected cells indicated that menin knockdown reduces E2-dependent transcription of TFF1 about 4-fold (Fig. 2A). Immunoblot analysis of transfected cell lysates indicated a specific decrease of menin levels (Fig. 2B). Importantly, siRNA treatment did not affect expression of ERα or TBP, which were included as a loading control (Fig. 2B). This analysis indicates that menin is involved in hormone-dependent transcription of the ERα-responsive TFF1 gene.

Ligand-induced recruitment of menin is required for H3K4me3 of the TFF1 promoter. The above experiments indicated that menin is important for regulation of E2-dependent TFF1 promoter activity. We investigated direct involvement of
menin by chromatin immunoprecipitation experiments. Using menin-specific antibodies, we found that the menin protein was recruited to the activated TFF1 promoter along with ERα and RNA polymerase II (Fig. 3A). Because menin is associated with HMT-complexes (9, 10), we examined the methylation status of H3K4 in chromatin immunoprecipitation assays. Interestingly, H3K4 trimethylation (H3K4me3) but not dimethylation (H3K4me2) was elevated after E2 treatment (Fig. 3B). It is important to note that upon E2 stimulation, histone H3 levels on the TFF1 gene are lowered. This suggests that removal of nucleosomes is involved in TFF1 activation as was also observed for activated yeast promoters (23).

We used our siRNA knockdown approach to investigate whether menin is also critical for elevated H3K4me3 levels at the TFF1 promoter. MCF-7 cells were treated with menin siRNAs before E2 stimulation and formaldehyde cross-linking. In these cells, but not in control siRNA-treated cells, induced H3K4me3 levels were severely diminished (Fig. 3D). In this setup, the reduction is not due to a global effect on H3K4me3 levels (Fig. 2B). Interestingly, upon E2 stimulation, we observed a reduction in total histone H3 associated with the TFF1 promoter in lamin knockdown cells but not in menin knockdown cells (Fig. 3C). Together, our experiments indicate that the menin tumor suppressor protein links activating histone H3K4 methylation to transcription stimulation of the endogenous TFF1 gene.

Ligand-dependent interaction of menin and ERα. We noticed that menin contains an evolutionarily conserved LXXLL (amino acids 263-267) and several LXXLL-like motifs, which are involved in binding of transcriptional coactivators to liganded nuclear receptors (16). As our experiments indicated that menin can provide a critical link in the activation of nuclear receptors, we did two different assays to determine whether menin can interact directly with ERα. First, we found that menin interacted with the AF2 domain of ERα in a yeast two-hybrid experiment in the presence of ethanol, 1 μmol/L E2, or 4OH-Tamoxifen. Relative β-galactosidase activities. Columns, mean; bars, SE. Testing LexA-menin in combination with B42 alone resulted in 8-fold lower levels than LexA-menin and B42-ERα in the presence of E2 (data not shown). C, menin interacts directly with activated ERα. Glutathione beads were coated with purified GST, GST-mERα-AF2, GST-hJunD, and GST-NF-κB proteins and incubated with recombinant menin in the absence or presence of E2. Retention of menin protein was determined by immunoblotting.

Figure 4. Menin interacts directly with activated ERα. A and B, binding of menin to hERα-AF2 or the M547A/L548A helix 12 mutant was investigated in a yeast two-hybrid experiment in the presence of ethanol, 1 μmol/L E2, or 4OH-Tamoxifen. Relative β-galactosidase activities. Columns, mean; bars, SE. Testing LexA-menin in combination with B42 alone resulted in 8-fold lower levels than LexA-menin and B42-ERα in the presence of E2 (data not shown). C, menin interacts directly with activated ERα. Glutathione beads were coated with purified GST, GST-mERα-AF2, GST-hJunD, and GST-NF-κB proteins and incubated with recombinant menin in the absence or presence of E2. Retention of menin protein was determined by immunoblotting.
the transfected proteins in E2-treated 293T cells, which would be in agreement with a low-affinity interaction. Nevertheless, the experiments of Fig. 4 show that menin can act interact directly with ERα in a hormone-dependent manner.

**MEN1 mutations can disrupt ERα association and activation.** To determine the clinical relevance of the menin-ERα interaction, 11 disease-related MEN1 mutants were tested in the yeast two-hybrid assay. These mutations have all been reported in the literature (25–30). Most mutations disrupted the ligand-dependent interaction between menin and ERα (Fig. 5A). For example, the L264P and L267P mutations in the putative LXLL-motif were completely defective for ERα interaction as expected. However, other disease-related mutants like G305D and H317R displayed no defect.

We decided to analyze the coactivator properties of four MEN1 mutants. Interestingly, none of these selected mutants increased E2-dependent ERα activity in the luciferase reporter assay (Fig. 5B). Previously, it was shown that MEN1 mutations can result in reduced steady-state levels of overexpressed menin (31). However, analysis of transfected cell lysates indicated the menin proteins were expressed to similar levels in our experiment (Fig. 5B).

**Discussion**

In this study, we show that menin, the product of the **MEN1** tumor suppressor gene, is a coactivator for ERα-mediated transcription by increasing H3K4 methylation of the E2-responsive TFF1 promoter. ERα and VDR were chosen as model nuclear receptors for our interaction studies. We propose that a direct interaction between menin and ligand-activated nuclear receptors is responsible for enhanced H3K4 trimethylation. This is most clearly shown by the siRNA knockdown experiment of Fig. 3. Taken together, our results reveal a specific pathway for alterations in histone methylation, and they bear important implications for the etiology of the MEN1 syndrome.

We show for the first time that E2-dependent activation of the TFF1 promoter is accompanied by increased levels of H3K4me3 and a decrease in histone H3 association. Previous analyses indicated that H3K4me3 correlates with the transcriptional activity of genes and occurs at their 5' end (11, 12). The direct functional consequences of increased H3K4me3 levels are not known yet. Our observations that menin knockdown prevents both H3K4me3, and a reduction in total H3 (Fig. 3) suggests a functional link between these events. Possibly, chromatin remodelers analogous to the yeast Chd1 or Isw1 proteins (32, 33) recognize the H3K4me3 mark and are involved in nucleosome removal from the activated promoter. Alternatively, H3K4 methylation may be linked to H4K16 modification by the acetyltransferase MOF (34). Recently, H4-K16 acetylation has been shown to inhibit chromatin compaction (35).

Recruitment of transcription cofactors and basal transcription factors was shown to occur in a cyclical pattern during ligand-dependent transcription of the TFF1 gene (14, 21, 22). This also involved dimethylation of H3R17 and H4R3 and acetylation of H3K14 and H4K16 (22). Menin association and H3K4me3 could also be cyclical. However, H3K4me3 marks are believed to be relatively persistent (36). Consistent with this, for androgen receptor (AR) target promoters, ligand-dependent increases in H3K4me3 do not display a cyclical pattern (37). In addition to this, it would be interesting to test menin involvement in AR function, as a reduced level of H3K4me2 (H3K4me3 was not tested) is one of the markers for an increased risk of prostate tumor recurrence (38).

Several mammalian SET-domain containing proteins, including MLL1, MLL2, SET7/9, and SMYD3, can methylate H3K4 (reviewed in ref. 39). We propose that the SET-domain containing MLL1 (mixed lineage leukemia) and/or MLL2/TRX2 (trithorax homologue 2) proteins are responsible for the elevated H3K4me3 levels at the TFF1 locus. As an integral component (9, 10), menin may act to link MLL1/MLL2 complexes to activated nuclear receptors in general. In accordance with this proposal, experiments in Drosophila showed that the activated edcsyneceptor (EcR) recruits the HMT activity of the trithorax-related gene product TRR (40). Interestingly, the RXR orthologue Ultraspiracle is the EcR heterodimerization partner, and we observed that menin can interact with the murine RXR in a ligand-dependent manner (data not shown).
shown). The model of menin connecting an activated nuclear receptor with MLL1/MLL2 complexes predicts that the G305D and H317R mutations, which are not defective for nuclear receptor interaction (Fig. 5A), will be disturbed in MLL1/MLL2-muten complex formation as was suggested by the analysis of other menin mutants (9).

A consistent reduction of global H3K4me3 levels was observed in pancreatic tumors from MEN1−/− transgenic mice (41). This suggests that other transcriptional activators besides activated nuclear receptors may also require menin for efficient H3K4 trimethylation. Most likely, this includes previously identified menin interactors. The fact that a reduction in H3K4me3 was not apparent in menin knockdown cells (Fig. 2B) indicates either persistence of the H3K4me3 mark during the time course of knockdown experiments, or that menin/MLL complexes do not represent the predominant H3K4me3 activity in MCF-7 cells. It should be noted that a reduction of global MLL levels as described by Milne et al. (13) in MEN1-associated pancreatic adenomas may contribute to the reduction of global H3K4me3.

The MEN1 syndrome is rather diverse in its clinical manifestations, and nuclear receptors have many functions in organs affected in MEN1 patients. For example, elevated levels of parathyroid hormone are very common in these patients. In the normal situation, activation of VDR will inhibit production and release of PTH. As reported here, menin is a regulator of ERα and VDR function, and inactivation of menin leads to disruption of ERα-mediated transcription. In the case of VDR, our findings could help explain elevated PTH production in MEN1 patients. Interestingly, polymorphisms of the VDR gene have been associated with hyperparathyroidism (reviewed in ref. 42). Prolactinomas are also a common manifestation of MEN1. ERα has a direct effect on prolactin production in the pituitary gland and is expressed in pituitary adenomas (43).

At least two mechanisms have been proposed for MEN1-associated tumorigenesis. First, inactivation of menin may allow JunD to promote tumor growth (44). Second, loss of regulation by menin of the p18 and p27 tumor suppressor genes may lead to the development of MEN1 tumors (13). Our finding that menin is critical for linking hormone action to H3K4 trimethylation and gene activation provides additional clues for the etiology and tissue specificity of the manifestations of the MEN1 syndrome. Further studies aimed at restoring nuclear receptor function in MEN1 tumors may eventually yield novel therapeutic options.

Acknowledgments

Received 12/14/2005; revised 2/21/2006; accepted 2/22/2006.


The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank G. Weber (Karolinska Institute, Stockholm, Sweden), S. Agarwal (NIDDK, Bethesda, MD), L. Burns (NIDDK, Bethesda, MD), M. Bengus (CNRS/INSERM/ULP, Illkirch, France), D. Heery (University of Nottingham, Nottingham, United Kingdom), and E. Kalkhoven (University Medical Center, Utrecht, the Netherlands) for plasmids; I.A. Kammer for stimulating discussions; R.A. Wiering for assistance in the yeast two-hybrid assay; O. van Beekum, R. Heiderman, S. Denissov, the Timmers laboratory, and, especially, P. Pijnappel, F. van Werven, and S. Jayne for advice and assistance.

References


Menin Links Estrogen Receptor Activation to Histone H3K4 Trimethylation

Koen M.A. Dreijerink, Klaas W. Mulder, G. Sebastiaan Winkler, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/66/9/4929

Cited articles
This article cites 44 articles, 16 of which you can access for free at:
http://cancerres.aacrjournals.org/content/66/9/4929.full#ref-list-1

Citing articles
This article has been cited by 22 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/66/9/4929.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.